
- Location
- Burg. Oudlaan 50, Rotterdam
- Telephone
- 0104088564
- versteegh@imta.eur.nl
More information
Profile
Matthijs Versteegh, PhD (Utrecht, The Netherlands, 1984) is director at the institute for Medical Technology Assessment (iMTA) at Erasmus University of Rotterdam. Matthijs holds an undergraduate in health sciences, and a master (cum laude) in science & technology studies (Maastricht University). He obtained his PhD in health economics on quantifying quality of life for economic evaluations of health from Erasmus University of Rotterdam. After completing his PhD, Matthijs worked for consultancy firm Ecorys (Dutch office) on projects for the European Commission (DG SANCO), the World Health Organisation (in Moldova and Kazakhstan), the World Bank (in India) and large regional variation studies for the Dutch board of Health Insurance (Zorginstituut Nederland). Matthijs is a member of the EuroQoL research foundation and the ‘Jonge Zorgdenktank’.
- M.M. Versteegh, I. Corro Ramos, N.C. Buyukkaramikli, A. Ansaripour, V.T. Reckers - Droog & W.B.F. Brouwer (2019). Severity-Adjusted Probability of Being Cost Effective. Pharmacoeconomics (Print), 37, 1155-1163. doi: 10.1007/s40273-019-00810-8 [go to publisher's site]
- M.M. Versteegh (2016). Doelmatige gezondheidszorg: hoe besteden we onze euro's het beste? In M M Levi (Ed.), De dokter en het geld. Diagnosis uitgevers
- M.M. Versteegh, K. Vermeulen, S.M.A.A. Evers, G.A. de WIt, R. Prenger & E.A. Stolk (2016). Dutch Tariff for the Five-Level Version of EQ-5D. Value in Health, 19 (4), 343-352. doi: 10.1016/j.jval.2016.01.003
- M.M. Versteegh (2016). Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis. Pharmacoeconomics (Online), 34, 1133-1144. doi: 10.1007/s40273-016-0421-0
- M.M. Versteegh & W.B.F. Brouwer (2016). Patient and general public preferences for health states: A call to reconsider current guidelines. Social Science & Medicine, 165, 66-74. doi: 10.1016/j.socscimed.2016.07.043
- M.M. Versteegh, A. Leunis, C.A. de Uyl-de Groot & E.A. Stolk (2012). Condition- Specific Preference-Based Measures: Benefit or Burden? Value in Health, 15, 504-513. doi: 10.1016/j.jval.2011.12.003
- M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. de Uyl-de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32, 554-568. doi: 10.1177/0272989X11427761
- M.M. Versteegh, I. Corro Ramos, N.C. Buyukkaramikli, A. Ansaripour, V.T. Reckers - Droog & W.B.F. Brouwer (2019). Severity-Adjusted Probability of Being Cost Effective. Pharmacoeconomics (Print), 37, 1155-1163. doi: 10.1007/s40273-019-00810-8 [go to publisher's site]
- M.M. Versteegh (2016). Doelmatige gezondheidszorg: hoe besteden we onze euro's het beste? In M M Levi (Ed.), De dokter en het geld. Diagnosis uitgevers
- M.M. Versteegh, K. Vermeulen, S.M.A.A. Evers, G.A. de WIt, R. Prenger & E.A. Stolk (2016). Dutch Tariff for the Five-Level Version of EQ-5D. Value in Health, 19 (4), 343-352. doi: 10.1016/j.jval.2016.01.003
- M.M. Versteegh (2016). Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis. Pharmacoeconomics (Online), 34, 1133-1144. doi: 10.1007/s40273-016-0421-0
- M.M. Versteegh & W.B.F. Brouwer (2016). Patient and general public preferences for health states: A call to reconsider current guidelines. Social Science & Medicine, 165, 66-74. doi: 10.1016/j.socscimed.2016.07.043
- M.M. Versteegh, A. Leunis, C.A. de Uyl-de Groot & E.A. Stolk (2012). Condition- Specific Preference-Based Measures: Benefit or Burden? Value in Health, 15, 504-513. doi: 10.1016/j.jval.2011.12.003
- M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. de Uyl-de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32, 554-568. doi: 10.1177/0272989X11427761
- T.A. Kanters, J.J. Brugts, O.C. Manintvelt & M.M. Versteegh (2021). Burden of providing informal care for patients with atrial fibrillation. Value in Health, 24 (2), 236-243. doi: 10.1016/j.jval.2020.09.011
- J.J. Brugts, J.F. Veenis, S.P. Radhoe, G. LInsssen, M. Van Gent, C.J.W. Borleffs, J. van Ramhorst, P. van Pol, R. Tukkie, R. Spee, M. Emans, W. Kok, V. van Halm, L. Handoko, S. Beeres, M. Post, E. Boersma, M.J. Lenzen, O.C. Manintveld, H. Koffijberg, P.H.M. van Baal, M.M. Versteegh, T. Smilde, L. van Heerebeek, M. Rienstra, A. Mosterd, P. Delnoy, F.W. Asselbergs, H. Brunner-La Rocca & R. de Boer (2020). A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure : Design and rationale of the MONITOR HF multicentre randomised clinical trial. Netherlands Heart Journal, 28 (1), 16-26. doi: 10.1007/s12471-019-01341-9
- M.F. Jonker, B. Donkers, L.M.A. Goossens, R.J. Hoefman, L.J. Jabbarian, E. De Bekker-Grob, M.M. Versteegh, G. Harty & S. Wong (2020). Summarizing Patient Preferences for the Competitive Landscape of (Multiple Sclerosis) Treatment Options. Medical Decision Making, 40 (2), 198-211. doi: 10.1177/0272989X19897944
- V.J. Wester, S. de Groot, T.A. Kanters, L. Wagner, J. Ardesch, I. Corro Ramos, M.J. Enders-Slegers, M. de Ruiter, S. le Cessie, J. Los, G. Papageorgiou, N.J.A. van Exel & M.M. Versteegh (2020). Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands: Study Protocol for a Stepped Wedge Randomized Controlled Trial (EPISODE). FRONTIERS IN NEUROLOGY, 11 (3). doi: 10.3389/fneur.2020.00003 [go to publisher's site]
- M.M. Versteegh, A.E. Attema & C.A. Uyl - de Groot (2019). Is verlies winst? Stoppen met TNF-α-blokkers. Nederlands Tijdschrift voor Geneeskunde.
- A. Sajjad, M.M. Versteegh, J. van Busschbach, J. Simon & L. Hakkaart-van Roijen (2019). In Search of a Pan-European Value Set; Application for Eq-5d-3l: The Pecunia Project. Value in Health, 22, S815. doi: 10.1016/j.jval.2019.09.2204
- M.M. Versteegh, I. Corro Ramos, N.C. Buyukkaramikli, A. Ansaripour, V.T. Reckers - Droog & W.B.F. Brouwer (2019). Severity-Adjusted Probability of Being Cost Effective. Pharmacoeconomics (Print), 37, 1155-1163. doi: 10.1007/s40273-019-00810-8 [go to publisher's site]
- M. Gheorghe, R.J. Hoefman, M.M. Versteegh & J. van Exel (2019). Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool. Pharmacoeconomics (Print), 37 (1), 93-103. doi: 10.1007/s40273-018-0706-6
- A.A.H. de Hond, P.L.H. Bakx & M.M. Versteegh (2019). Can time heal all wounds? An empirical assessment of adaptation to functional limitations in an older population. Social Science & Medicine, 222, 180-187. doi: 10.1016/j.socscimed.2018.12.028 [go to publisher's site]
- S. de Groot, W.K. Redekop, M.M. Versteegh, S. Sleijfer, E. Oosterwijk, L.A.L.M. Kiemeney & C.A. Uyl - de Groot (2018). Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Quality of Life Research, 27, 115-124. doi: 10.1007/s11136-017-1704-4
- W.B.F. Brouwer, P.H.M. van Baal, N.J.A. van Exel & M.M. Versteegh (2018). When is it too expensive? Cost-effectiveness thresholds and health care decision-making. European Journal of Health Economics (HEPAC). doi: 10.1007/s10198-018-1000-4
- P.H.M. van Baal, M.S. Perry-Duxbury, P.L.H. Bakx, M.M. Versteegh, E.K.A. van Doorslaer & W.B.F. Brouwer (2018). A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. Health Economics, 28 (1), 87-100. doi: 10.1002/hec.3831
- I. Corro Ramos, M.M. Versteegh, J.M. Koenders, G.C. Linssen, J. Meeder & M.P.M.H. Rutten - van Molken (2017). Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. Value in Health. doi: 10.1016/j.jval.2017.05.013
- M.F. Jonker, A.E. Attema, B. Donkers, E.A. Stolk & M.M. Versteegh (2017). Are Health State Valuations from the General Public Biased? A Test of Health State Reference Dependency Using Self-assessed Health and an Efficient Discrete Choice Experiment. Health Economics, 26 (12), 1534-1547. doi: 10.1002/hec.3445
- M.M. Versteegh, S. Knies & W.B.F. Brouwer (2016). From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare. Pharmacoeconomics (Print), 34 (11), 1071-1074. doi: 10.1007/s40273-016-0431-y
- M.M. Versteegh, K. Vermeulen, S.M.A.A. Evers, G.A. de WIt, R. Prenger & E.A. Stolk (2016). Dutch Tariff for the Five-Level Version of EQ-5D. Value in Health, 19 (4), 343-352. doi: 10.1016/j.jval.2016.01.003
- M.M. Versteegh (2016). Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis. Pharmacoeconomics (Online), 34, 1133-1144. doi: 10.1007/s40273-016-0421-0
- M.M. Versteegh & W.B.F. Brouwer (2016). Patient and general public preferences for health states: A call to reconsider current guidelines. Social Science & Medicine, 165, 66-74. doi: 10.1016/j.socscimed.2016.07.043
- D.T. Arnold, D. Rowen, M.M. Versteegh, A. Morley, C.E. Hooper & N.A. Maskell (2015). Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma. Health and Quality of Life Outcomes, 13 (6). doi: 10.1186/s12955-014-0196-y
- S. de Groot, A.J. Rijnsburger, M.M. Versteegh, J.M. Heymans, S. Kleijnen, W.K. Redekop & I. Verstijnen (2015). Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers. BMJ Open, 5::e007241. doi: 10.1136/bmjopen-2014-007241
- R. Crott, M.M. Versteegh & C.A. de Uyl-de Groot (2013). An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences. Quality of Life Research, 22 (5), 1045-1054. doi: 10.1007/s11136-012-0220-9.
- A.E. Attema, Y. Edelaar-Peeters, M.M. Versteegh & E.A. Stolk (2013). Time trade-off: one methodology, different methods. European Journal of Health Economics (HEPAC), 14 (1), 53-64. doi: 10.1007/s10198-013-0508-x
- M.M. Versteegh, A.E. Attema, M. Oppe, N. Devlin & E.A. Stolk (2013). Time to tweak the TTO: results from a comparison of alternative specifications of the TTO. European Journal of Health Economics (HEPAC), 14 (1), 43-51. doi: 10.1007/s10198-013-0507-y
- B.M.F. Janssen, M. Oppe, M.M. Versteegh & E.A. Stolk (2013). Introducing the composite time trade-off: a test of feasibility and face validity. The European Journal Of Health Economics, 14, 5-13. doi: 10.1007/s10198-013-0503-2
- A.E. Attema, M.M. Versteegh, M. Oppe, W.B.F. Brouwer & E.A. Stolk (2013). LEAD TIME TTO: LEADING TO BETTER HEALTH STATE VALUATIONS. Health Economics, 22 (4), 376-392. doi: 10.1002/hec.2804
- A.E. Attema & M.M. Versteegh (2013). Would you rather be ill now, or later? Health Economics, 22 (12), 1496-1506. doi: 10.1002/hec.2894
- M.M. Versteegh, A. Leunis, C.A. de Uyl-de Groot & E.A. Stolk (2012). Condition- Specific Preference-Based Measures: Benefit or Burden? Value in Health, 15, 504-513. doi: 10.1016/j.jval.2011.12.003
- M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. de Uyl-de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32, 554-568. doi: 10.1177/0272989X11427761
- C. de Sonneville-Koedoot, M.M. Versteegh & J.S. Yaruss (2011). Psychometric evaluation of the Dutch translation of the Overall Assessment of the Speaker's Experience of Stuttering for adults (OASES-A-D). Journal of Fluency Disorders, 36, 222-230. doi: 10.1016/j.jfludis.2011.03.002
- M.M. Versteegh, D. Rowen, J.E. Brazier & E.A. Stolk (2010). Mapping onto EQ-5D for patients in poor health. Health and Quality of Life Outcomes, 8 (141), 1-26. doi: 10.1186/1477-7525-8-141
- M.M. Versteegh, A.E. Attema & C.A. Uyl - de Groot (2019). Is verlies winst? Stoppen met TNF-alfaremmers. Nederlands Tijdschrift voor Geneeskunde, 163:D3709. [go to publisher's site]
- M. Canoy, M.M. Versteegh, A.L. Bredenoord & M. Verweij (2018). De prijs van zorg op een goudschaaltje. Medisch Contact.
- M. Canoy, A.L. Bredenoord, M. Verweij & M.M. Versteegh (2018). Welke patiënten worden de dupe? NRC Handelsblad (print).
- M.M. Versteegh (2017). Vaar niet op deernis voor enkelen bij duur medicijn. NRC Handelsblad (print).
- M.M. Versteegh (2016). Doelmatige gezondheidszorg: hoe besteden we onze euro's het beste? In M M Levi (Ed.), De dokter en het geld. Diagnosis uitgevers
- G. de Graaf, S. de Groot, V.J. Wester, H.E. Vellekoop, M.M. Versteegh & M. Rutten-van Molken (2019). WAARDEBEPALING, IMPLEMENTATIE EN BEKOSTIGING VAN VOORSPELLENDE TESTEN IN NEDERLAND. (Extern rapport). : ZonMW [go to publisher's site]
- M.M. Versteegh (2014, april 10). Quality of Life in Economic Evaluations of Health. EUR (187 pag.) Prom./coprom.: prof.dr. W.B.F. Brouwer.
(external) researcher
- University
- Erasmus University Rotterdam
- School
- Erasmus School of Health Policy & Management
- Department
- Health Technology Assessment (HTA)
- Country
- The Netherlands
- Telephone
- 0104088564
EuroQoL research foundation
- Role
- Member
- Obtained Wage
- no